Evidence map›Paper›PMID 37965256›Full record

ArticleFrontiers in cellular and infection microbiology2023

Xiyuan Bai, Deepshikha Verma, Cindy Garcia, Ariel Musheyev, Kevin Kim, Lorelenn Fornis, David E Griffith, Li Li, Nicholas Whittel, Jacob Gadwa and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Xiyuan Bai *Department of Academic Affairs, National Jewish Health, Denver, CO, United States.
Deepshikha Verma *Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Cindy GarciaDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
Ariel MusheyevDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
Kevin KimDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
Lorelenn FornisDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
David E GriffithDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
Li LiDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
Nicholas WhittelMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Jacob GadwaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Tamara OhanjanyanMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Matthew J EgglestonComplement Laboratory, Advance Diagnostics, National Jewish Health, Denver, CO, United States.
Manuel GalvanComplement Laboratory, Advance Diagnostics, National Jewish Health, Denver, CO, United States.
Brian M FreedDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Diane OrdwayMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Edward D ChanDepartment of Academic Affairs, National Jewish Health, Denver, CO, United States.
National Jewish Health · USColorado State University · USUniversity of Colorado Denver · USUniversity of Colorado Anschutz Medical Campus · US

Funding

CSU Infectious Disease Research and Response Training ProgramT32AI162691 · NIAID · COLORADO STATE UNIVERSITY · PI DEAN, GREGG A · 2021 to 2025
$2.1M
CSRD VA I01 CX001452NIAID NIH HHS T32 AI162691
6 · The paper itself

Abstract

Introduction: A strong epidemiologic link exists between cigarette smoke (CS) exposure and susceptibility to tuberculosis (TB). Macrophage and murine studies showed that CS and nicotine impair host-protective immune cells against Methods: We investigated whether CS-exposed Tregs could exacerbate Results: We found that exposure of primary human Tregs to CS extract impaired the ability of unexposed human macrophages to control an Discussion: Previous studies demonstrated that CS impairs macrophages and host-protective T effector cells in controlling

Indexed as

Cigarette SmokingMycobacterium tuberculosisTuberculosisAnimalsHumansMiceNicotineT-Lymphocytes, RegulatoryNicotineadoptive transferautophagyCTLA-4macrophageT regulatory

Identifiers

PMID37965256
PMCPMC10641287
OpenAlexW4388196538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.